

Article

# Development of an Accurate and Rapid Antigen Assay for COVID-19 Diagnostics Using Saliva

Camille Troup<sup>1,2</sup>, Debnath Mukhopadhyay<sup>1,3</sup>, Tania Chakrabarty<sup>1,4</sup>, Anup Madan<sup>1,5</sup>, Sri Satyanarayana<sup>1,6</sup>, Shreefal Mehta<sup>1,7</sup>, and Su Dwarakanath<sup>1\*</sup>

<sup>1</sup> Kaya17, Livermore CA, <sup>2</sup>[camille@kaya17.com](mailto:camille@kaya17.com), <sup>3</sup>[debms12@yahoo.com](mailto:debms12@yahoo.com), <sup>4</sup>[chkrbrty2002@yahoo.com](mailto:chkrbrty2002@yahoo.com), <sup>5</sup>[Anup@kaya17.com](mailto:Anup@kaya17.com), <sup>6</sup>[Sri@kaya17.com](mailto:Sri@kaya17.com), <sup>7</sup>[shreefal@kaya17.com](mailto:shreefal@kaya17.com), \*Correspondence: [su@kaya17.com](mailto:su@kaya17.com)

**Abstract:** The global outbreak of COVID-19 highlighted the need for rapid and accurate diagnostic testing to control the spread of this highly contagious disease (1-5). Here, we describe the nCoVega COVID-19 antigen rapid test (~ 15min) that can detect the presence of the SARS-COV-2 virus particles from saliva sample on a portable device. The portable reader instrument, the Vega-200, has a small footprint and is designed for use at point of care settings. The test detects the fluorescence signal using wide-field illumination from antigen-antibody complexes captured on a special filter matrix (6). Results of this clinical evaluation of 183 subjects demonstrates that the nCoVega COVID-19 test performs at par with qRT-PCR tests (7) (gold standard) for both symptomatic and asymptomatic patients, with a strong inverse correlation between RFU (relative fluorescence units) and Ct counts (from RT-PCR) maintaining detection accuracy even at very low viral loads. The test has an analytical performance of 15.3 TCID<sub>50</sub>/mL, and 100% specificity for COVID-19 as compared to other human respiratory viruses, including other human coronaviruses. The working principle of this assay and test system can be used for developing other rapid, inexpensive antigen assays and it can offer an end-to-end, point-of-care solution to meet the continuous demand in tackling existing and emerging infectious diseases across the globe.

**Keywords:** Point of care; immuno-fluorescence, COVID-19; SARS-COV-2; antigen, saliva.

## 1. Introduction

The nCoVega COVID-19 Antigen test, developed by Kaya 17, Inc., is an antigen-capture assay intended for the qualitative detection of spike protein antigen from SARS-CoV-2 in saliva from individuals, as viral antigen is generally detectable in saliva during the acute phase of infection. Positive results indicate the presence of viral antigens. This antigen test can be performed by trained non-laboratory or laboratory technicians for point of care use or for general use in clinical labs and hospital settings. The test works on a simple portable instrument called Vega-200 using a custom cartridge, assay reagents, and Vega software. The workflow uses a QR code reader and printer for tracking patient information.

The vast majority of COVID-19 antigen tests utilize lateral flow technology, which has inherent limitations in terms of dynamic range, sensitivity and specificity (8-10). The current rapid antigen tests are approved for nasal or NP swab. Other approaches include magnetic force assisted ELISA, microfluidic ELISA and digital chromatographic immunoassays, all of which require costly and complex custom manufacturing.


The nCoVega test utilizes selective antigen-antibody complex capture via filtration on an inexpensive and easy to manufacture disposable cartridge, and wide-field fluorescence imaging designed to give results in a few minutes with very high sensitivity and specificity. The reader is designed to run on USB power and is portable, light with no moving parts. Test format is designed so that 30-50 tests per hour can be processed on one reader. The workflow for our end-to-end solution including the test and the system is shown below in figure 1.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

The novel nCoVega COVID19 Antigen test is a direct dual probe antigen capture test using two fluorescently labeled primary antibodies (S1 and S2 spike protein recombinant IgG) that bind to SARS-CoV-2 spike protein on viral particles present in a saliva sample. 43  
44  
45

The developed test therefore can be easily deployed for large-scale population testing under community health settings, hospitals, and at the point of care with minimal operator training. This rapid and inexpensive test could help with COVID-19 diagnosis and controlling the spread of the global pandemic. The test can also be used to support decisions on infection control strategies such as detecting and isolating asymptomatic cases that could spread the virus unknowingly. 46  
47  
48  
49  
50

## End to End Solution for COVID testing with Kaya17 Vega App



**Figure 1:** Schematic diagram showing the workflow for the nCoVega Test on the Vega-200 platform

The study described here investigates the overall accuracy and sensitivity of the nCoVega antigen test in comparison with a high sensitivity RT-PCR method as the gold standard (7) for diagnosis of COVID-19. 53  
54

## 2. Materials and Methods

Sample collection and processing: A saliva sample (approximately 200ul) is collected at the point of care testing by directly spitting into a vial that is placed in a syringe fitted with a filter. 1 mL of the proprietary sample processing reagent is added. A plunger is pushed to allow the treated saliva sample to pass through the filter and is collected in a second tube for antibody labeling. The filtrate is incubated with 30ul of fluorescently-labeled S1 and S2 antibodies for 10 minutes at room temperature. The mixture is then passed through a disposable vertical flow cartridge fitted with a proprietary capture matrix. The fluorescence signal from the captured antigen-antibody complex is recorded using a portable device equipped with wide-field illumination. 57  
58  
59  
60  
61  
62  
63  
64

Antibodies and conjugation: The S1 and S2 antibodies used in our test are purchased from GeneTex, TX and conjugated with a Biotium Mix-n-Stain CF 405L fluorophore (Biotium Inc, Fremont, CA, USA). The fluorophore used in our test has a large Stokes Shift with an excitation peak at 395nm and emission peak 65  
66  
67  
68

around 545 nm. S1 and S2 antibodies are conjugated using the Mix-n-Stain protocol following the manufacturer's protocol, which consists of direct labeling of the antibodies to the fluorophore via an NHS-ester covalent bond formation. The conjugated antibodies are then purified via spin column centrifugation and buffer exchanged into a PBS-based storage buffer. The CF dyes were carefully chosen for their superior brightness, photostability, large Stokes Shift, and resistance to hydrolysis offering superior performance over most dyes.

Instrument and data collection: The patient saliva sample labeled with fluorescent antibodies is placed on the cartridge inside a well, lined at the bottom with a capture matrix. An absorbent pad inside the cartridge holder to remove excess liquid and the unbound antibody. The bound antibody/antigen complex is selectively retained on the capture matrix via size exclusion mechanism. 500ul of wash reagent is added to the cartridge and allowed to wick through. Finally, 500ul of proprietary read reagent is added to the cartridge and the cartridge is immediately placed on the Vega-200 instrument for readout. The Vega-200 instrument records the fluorescence from the captured complex on the cartridge and reports a qualitative result (Positive or Negative). The system portable Vega-200 instrument is a fluorescence reader (U.S. Patent Application Serial Number: 16/690,589). The Vega analysis software, Patient ID software, an ID scanner with a QR code printer were all run on a standard PC. In addition, data reporting via a mobile device is also available.

#### Data availability

Detailed data directly used to generate each figure or table of this study are available within the article, Supplementary Information and source data are also provided with this paper.

#### Method used to determine LoD:

Concentrations ranging from  $1.6 \times 10^5$  TCID<sub>50</sub>/mL to  $1.0 \times 10^1$  TCID<sub>50</sub>/mL Heat killed Zeptomatrix SARS-CoV-2 (Cat. No. 0810587CFHI Lot No.324930) was spiked into artificial saliva matrix from Pickering laboratory (1700-0316).

Limit of Detection (LoD) for Kaya17 nCoVega test was determined by performing serial dilution (Table 1). A 10-fold serial dilution of was performed from 10,000, 1,000, 100, 10 and 0 of Heat Killed SARS CoV 2 from Zeptomatrix in triplicate in Artificial saliva matrix from Pickering laboratory (1700-0316) (Figure 2a). From this, the LoD was estimated as 15.3 TCID<sub>50</sub> per ml by Probit analysis (Figure 2b). Raw data is included in the supplementary material section (Table 1, supplementary materials section).

#### Cross reactivity (analytical specificity):

Each organism was tested in the absence or presence of Heat Killed SARS-CoV-2 from Zeptomatrix at 3 x LoD in Artificial saliva matrix from Pickering laboratory (1700-0316). The final concentration of the organisms is in the Table 3 below (the concentrations of 10<sup>6</sup> CFU/mL or higher for bacteria and 10<sup>5</sup> PFU/mL or higher for viruses is recommended). For some of the microorganisms, the stock concentration was lower than or equal to the recommended testing concentration. In such cases, these microorganisms were used at the stock concentration.

#### Microbial Interference Studies:

Each organism was tested in the absence or presence of Heat Killed SARS-CoV-2 from Zeptomatrix at 3 x LoD in Artificial saliva matrix from Pickering laboratory (1700-0316). The final concentration of the organisms is in the Table 4 below (the concentrations of 10<sup>6</sup> CFU/mL or higher for bacteria and 10<sup>5</sup> PFU/mL or higher for viruses is recommended). For some of the microorganisms, the stock concentration was lower than or equal to the recommended testing concentration. In such cases, these microorganisms were used at the stock concentration.

#### Endogenous Interference Studies

Each substance was tested in triplicate in the absence or presence of Heat Killed SARS-CoV-2 from Zeptomatrix at 3 x LOD in Artificial saliva matrix from Pickering laboratory (1700-0316). Substances for testing were selected based on the respiratory specimen's guidance in [http://www.accessdata.fda.gov/cdrh\\_docs/reviews/K112177.pdf](http://www.accessdata.fda.gov/cdrh_docs/reviews/K112177.pdf).

#### Hook Effect Testing:

To determine if the Kaya17 nCoVega Test suffers from any high dose Hook effect, increasing concentrations of Heat Killed SARS-CoV-2 from Zeptomatrix at 3 x LoD, were tested up to a concentration of 1.6 x 10<sup>5</sup> TCID<sub>50</sub>/mL. The starting material was spiked into a pooled negative saliva matrix obtained from healthy donors and confirmed negative for SARS-CoV-2. At each dilution, 500µL samples were added to Extraction buffer and tested using the nCoVega test.

#### Clinical Evaluation

A prospective, single center, comparative study for validation of a rapid point-of-care test for diagnosis of SARS-COV-2 infection was conducted to evaluate the clinical use of the Kaya17 nCoVega COVID-19 Antigen test for use with saliva specimens collected neat.

The Kaya17 nCoVega COVID-19 Antigen test was clinically validated by Infinity BiologiX (IBX) using 183 paired saliva and swab samples (79 positives and 104 negatives) collected by St. Rose Hospital, Hayward, CA as per KAYA-PROTOPOCT-007 Prospective Clinical Study Protocol. The Western IRB approval number for the clinical trial was IRB protocol #20204097. Informed consents were collected from each subject along with basic medical history. The samples utilized in the study were analyzed using an RT PCR assay (Control), PerkinElmer New Coronavirus Nucleic Acid Detection Kit.

The primary objective of the study was to demonstrate efficacy of the Kaya17 nCoVega COVID-19 Antigen test in a non-laboratory setting by verifying the sensitivity and specificity of the Kaya17 nCoVega COVID-19 Antigen test in detecting SARS-COV-2 in positive saliva samples (yields a "positive" result) and not detecting SARS-COV-2 in negative saliva samples (yields a "negative" result) when performed by non-laboratory personnel. The secondary objective in the same protocol was to demonstrate that non-laboratory healthcare providers can perform the Kaya17 nCoVega COVID-19 Antigen test accurately in the intended use environment to Support Point of Care (POC) Use. (Point of Care study). In addition, the accuracy of detection was assessed in asymptomatic and symptomatic patients from day 1 of symptoms.

The data generated from the clinical study were statistically analyzed as per the following techniques

- Positive percent agreement (PPA),
- Negative percent agreement (NPA),
- Overall percent agreement (OPA),
- Associated 95% Wilson score confidence intervals
- Concordance analysis of the Kaya17 nCoVega Antigen test RFU vs Ct values of PCR

Subject status (negative/positive) was determined using a receiver operating characteristic (ROC) curve cutoff analysis. The evaluation metrics included positive percent agreement (PPA), negative percent agreement (NPA), overall percent agreement (OPA), and the absolute value of the sensitivity minus the specificity.

Before testing any of the samples, sample cartridges with positive and negative controls were inserted on the Vega 200 instrument that recorded fluorescence from these samples in RFU. This allowed the Vega analysis software to decide the cut-off value to use when deciding on positive and negative COVID-19 calls for sample testing. Details of the result interpretation are cited below in their respective sections. Raw data for the plots are also included in the supplementary information section.

All test controls were examined prior to interpretation of results. If the controls were not valid, the samples were not analyzed using the kit/instrument. Additional kits or instruments are required to be validated prior to running samples. The test result was determined by cutoff values based on fluorescence measurements on the Vega-200 instrument (excitation at 395 nm and emission at 545 nm). A "POSITIVE" result is called by the Vega software if the fluorescence measurement of the sample is above baseline fluorescence that has been determined by running the negative control multiple times. If the fluorescence value is at or below baseline, a "NEGATIVE" result is called by the Vega software. The results are stored in a CSV file on the Vega Reader computer. Further details are provided in the supplementary section.


### 3. Results

For laboratory validation of the nCoVega COVID19 Antigen test, a number of different studies were conducted such as analytical performance testing, LOD, cross-reactivity, inclusion and exclusion panel testing and hook effect testing. The details of each of those tests served to establish the sensitivity and specificity of the assay and the results are presented below.

#### 3.1. Analytical Performance

##### 3.1.1. Limit of Detection (LoD) Determination

LoD studies were performed to determine the lowest detectable concentration of SARS-CoV-2 at which approximately 95% of all (true positive) replicates test positive.



**Figure 2 (a):** LoD determination and dynamic range based on data from Table 1 (see supplementary section) 179

180

From the ten-fold dilution series results in Table 1, the LoD can be determined as at least 10 TCID<sub>50</sub>/mL, since 181  
all samples with concentrations from 100000 TCID<sub>50</sub>/mL down to 10 TCID<sub>50</sub>/mL were above the 0 182  
TCID<sub>50</sub>/mL. At 10 TCID<sub>50</sub>/mL, one of the replicates showed negative result (0.299 (S6)). Hence the LoD was 183  
set at 20 TCID<sub>50</sub>/mL. Probit analysis not possible due to 100% assessment of positivity at all positive 184  
concentration levels. 185

The ability to detect SARS-CoV-2 with Kaya17 nCoVega test at 20 TCID<sub>50</sub> per ml was further confirmed by 186  
testing 20 replicates (Table 1a in supplementary section). 187

Limit of Blank (LoB) experiments were performed by running 20 samples at 0 TCID<sub>50</sub> per ml LOB (Table 1a in 188  
supplementary section). 189

### 3.1.2 Assay Cutoff Determination 190

Determining the assay cutoff was a key part of the data analysis. The assay cutoff determination for positives 191  
and negatives is determined using the Currie's method (11) and CLSI EP17 guidance (12) for our qualitative 192  
purposes as follows. 193

From the guidance, the LoB' is defined as: 194

$$\text{LoB}' = \text{MB} + \text{Cp} \cdot \text{SDB} \quad 195$$

where M refers to the mean of "blank" samples and Cp is the multiplier and SDB is the Standard Deviation 196  
of the Blank Samples. As the data are very precise, in this case using a two-sided 5% significance level, Cp is 197  
defined as 198

$$\text{Cp} = \frac{1.96}{1 - \left(\frac{1}{4(B-K)}\right)} \quad \text{Cp} = 1.96 / (1 - (1/4(B-K))) \quad 199$$

where B is the total number of blank replicates and K is the number of blank samples. 200

201

Therefore, from the data in the spreadsheet (see supplementary section), the LOB' is calculated as: 202

$$\text{LoB}' = 0.9311 + 1.9861 \cdot 0.0027 = 0.9364 \text{ or } 0.936. \quad 203$$

Next, per the guidance, the LOD' can be calculated as: 204

$$\text{LoD}' = \text{LoB}' + \text{Cp} \cdot \text{SDL} = 0.9364 + 1.9861 \cdot 0.00266 = 0.94168 \text{ or } 0.942. \quad 205$$

where  $\text{Cp} = 1.96 / [1 - (1/4 \cdot (N_{\text{replicates}} - N_{\text{samples}}))] = 1.96 / [1 - (1/4 \cdot (20 - 1))] = 1.9861.$  206

and  $\text{SDL} = 0.00266$  is the standard deviation of the positive low concentration samples with appropriate 207  
provision for degrees of freedom depending on the number of samples used to obtain the total replicates. 208

Therefore, if the LoB' is taken as the cutoff (11), then we can establish a conservative equivocal zone between 209  
the LoB' and the LoD' as between 0.936 and 0.942 mean RR with the actual cutoff as 0.939 (as determined by 210  
ROC curve methodology in clinical evaluation (12)). Therefore, if a patient were to test in this equivocal 211

zone, their result should be assigned as 'Indeterminate' and a retest is performed. 212  
213

### 3.1.3 Cross-reactivity (Analytical Specificity) 214

We performed cross-reactivity studies for Kaya17 nCoVega test using a panel of related pathogens, normal or 215  
pathogenic flora that are reasonably found in the clinical specimen. Also, the high prevalence disease agents 216  
likely to be encountered in the clinical specimen were tested for specificity of the test and the results showed 217  
no potential cross-reactivity with the Kaya17 nCoVega test with these agents, including various 218  
microorganisms and pathogens. 219

Table 3: Results of Cross-reactivity study. 220

Microorganism	Source	Concentration	Cross-Reactivity (Yes/No)
Human coronavirus 229E	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 negative)
Human coronavirus OC43	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Human coronavirus NL63	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
MERS coronavirus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Adenovirus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Human Metapneumovirus (hMPV)	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Parainfluenza virus Type 1	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Parainfluenza virus Type 2	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Parainfluenza virus Type 3	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Parainfluenza virus Type 4a	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Influenza A H3N2 (Wisconsin/67/05)	BEI Resources	5.4 x 10 <sup>4</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Influenza A H1N1	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Influenza B (Florida/02/06)	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Enterovirus Type 68	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Respiratory syncytial Virus Type B	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Rhinovirus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
SARS-CoV	BEI Resources	1x10 <sup>5</sup> PFU/mL	No (3/3 Negative)
Herpes Simplex Virus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 Negative)
Epstein Barr Virus	Zeptomatrix	1.03x10 <sup>3</sup> cp/mL	No (3/3 Negative)
Haemophilus influenzae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Streptococcus pneumoniae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Streptococcus pyogenes	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Candida albicans	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Bordetella pertussis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Chlamydomphila pneumoniae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Legionella pneumophila	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Mycobacterium tuberculosis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Pneumocystis jirovecii	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Pseudomonas Aeruginosa	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Staphylococcus Epidermidis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Streptococcus Salivarius	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Mycoplasma pneumoniae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Pooled human Kaya17 nasal wash	Kaya17	14% v/v	No (3/3 Negative)
Elkenella corrodens	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Streptococcus mutans	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Staphlococcus aureus	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Neisseria Meningitidis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Nocardia asteriods	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Moraxella catarrhalis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)
Streptococcus mitis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 Negative)

221

222

### 3.1.4. Microbial Interference Studies

223

Microbial Interference for Kaya17 nCoVega test was evaluated by using a panel of related pathogens, normal or pathogenic flora that are reasonably found in the clinical specimen. Also, high prevalence disease agents

224

225



were tested for specificity to demonstrate that false negatives do not occur when SARS-CoV-2 is present in a specimen with other microorganisms.

226  
227

Table 4: Results of Microbial Interference studies

228

Microorganism	Source	Concentration	Interference (Yes/No)
Human coronavirus 229E	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Human coronavirus OC43	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Human coronavirus NL63	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
MERS coronavirus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Adenovirus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Human Metapneumovirus (hMPV)	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Parainfluenza virus Type 1	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Parainfluenza virus Type 2	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Parainfluenza virus Type 3	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Parainfluenza virus Type 4a	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Influenza A H3N2 (Wisconsin/67/05)	BEI Resources	5.4 x 10 <sup>4</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Influenza A H1N1	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Influenza B (Florida/02/06)	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Enterovirus Type 68	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Respiratory syncytial Virus Type B	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Rhinovirus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
SARS-CoV	BEI Resources	1x10 <sup>5</sup> PFU/mL	No (3/3 positive)
Herpes Simplex Virus	Zeptomatrix	1 x 10 <sup>5</sup> TCID <sub>50</sub> /mL	No (3/3 positive)
Epstein Barr Virus	Zeptomatrix	1.03x10 <sup>3</sup> cp/mL	No (3/3 positive)
Haemophilus influenzae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Streptococcus pneumoniae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)

229

Streptococcus pyogenes	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Candida albicans	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Bordetella pertussis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Chlamydomphila pneumoniae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Legionella pneumophila	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Mycobacterium tuberculosis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Pneumocystis jirovecii	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Pseudomonas Aeruginosa	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Staphylococcus Epidermidis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Streptococcus Salivarius	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Mycoplasma pneumoniae	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Pooled human Kaya17 nasal wash	Kaya17	14% v/v	No (3/3 positive)
Elkenella corrodens	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Streptococcus mutans	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Staphloccus aureus	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Neisseria Meningitidis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Nocardia asteriods	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Moraxella catarrhalis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)
Streptococcus mitis	Zeptomatrix	1 x 10 <sup>6</sup> CFU/mL	No (3/3 positive)

230

### 3.1.5. Endogenous Interference Substances Studies

231

The following study was conducted to investigate whether potentially interfering substances, which may be found in the mouth and throat of symptomatic subjects (including over-the-counter medications), cross-react or interfere with the detection of SARS-CoV-2 using the Kaya17 nCoVega test. There was no interference with any of the tested materials in the study as described in Table 5.

232

233

234

235

236

237

Table 5: Results of Interference Studies

Interfering Substance	Concentration	Interference (Yes/No)
Clarispray	50mcg	No
		(3/3 Negative, 3/3 Positive)
Blood (human)	5%	No
		(3/3 Negative, 3/3 Positive)
Mucin	5 mg/mL	No
		(3/3 Negative, 3/3 Positive)
Fluticasone Propionate Flovont HFA	110mcg	No
		(3/3 Negative, 3/3 Positive)
Ventolin HFA Albuterol	90mcg	No
		(3/3 Negative, 3/3 Positive)
Budesonide and Formoterol Fumarate Dihydrate	80mcg/4.5mcg	No
		(3/3 Negative, 3/3 Positive)
Anefrin oxymetazoline HCl	0.05% v/v	No
		(3/3 Negative, 3/3 Positive)
Azelastine HCl	137mcg	No
		(3/3 Negative, 3/3 Positive)
Sore Throat Phenol Spray	15% v/v	No
		(3/3 Negative, 3/3 Positive)
Montelukast (Singular)	0.5mg	No
		(3/3 Negative, 3/3 Positive)
Loratadine (Claritin)	0.15 mg/dL	No
		(3/3 Negative, 3/3 Positive)
Human Genomic DNA	10 ug.mL	No
		(3/3 Negative, 3/3 Positive)
Nyquil (Acetaminophen, Doxylamine succinate, Dextromethorphan HBr)	2 mg/mL	No
		(3/3 Negative, 3/3 Positive)
Toothpaste (Colgate)	0.5% v/v	No
		(3/3 Negative, 3/3 Positive)

Crest/Listerine Mouthwash (Eucalyptol, menthol, Methyl Salicylate, Thymol)	5% v/v	No (3/3 Negative, 3/3 Positive)
Zinc	10mg/mL	No (3/3 Negative, 3/3 Positive)
Emergen-C	10mg/mL	No (3/3 Negative, 3/3 Positive)
Chloraseptic (Menthol/Benzocaine)	1.5 mg/mL	No (3/3 Negative, 3/3 Positive)
CVS Nasal Drops (Phenylephrine)	15% v/v	No (3/3 Negative, 3/3 Positive)
Afrin (Oxymetazoline)	15% v/v	No (3/3 Negative, 3/3 Positive)
CVS Nasal Spray (Cromolyn)	15% v/v	No (3/3 Negative, 3/3 Positive)
Zicam	5% v/v	No (3/3 Negative, 3/3 Positive)
Homeopathic (Alkalol)	1:10 Dilution	No (3/3 Negative, 3/3 Positive)
Sore Throat Phenol Spray	15% v/v	No (3/3 Negative, 3/3 Positive)
Robitussin	2 mg/mL	No (3/3 Negative, 3/3 Positive)
Alcohol (Ethanol)	5%	No (3/3 Negative, 3/3 Positive)
Nicotine	0.03 mg/mL	No (3/3 Negative, 3/3 Positive)
Vaseline (Petroleum Jelly)	15% v/v	No (3/3 Negative, 3/3 Positive)
Tamiflu (Oseltamivir Phosphate)	5mg/mL	No (3/3 Negative, 3/3 Positive)
Tobacco (Nicotine, Tar, Carbon Monoxide, Formaldehyde, Ammonia, Hydrogen Cyanide, Arsenic, and DDT)	0.05mg/mL	No (3/3 Negative, 3/3 Positive)

240

241

### 3.2 *High-dose Hook Effect:*

242

The Weibull statistical model was used for the data analysis (x axis=log<sub>10</sub> TCID<sub>50</sub> copies; y axis =Raw Average). The analysis showed that at the top end of the assay (1.6 x 10<sup>5</sup> TCID<sub>50</sub> copies) there is a plateau. This provides evidence that a Hook effect does not exist for this assay up to 1.6 x 10<sup>5</sup> TCID<sub>50</sub> copies. The model fits, as measured by the correlation and coefficient of determination, were each about 0.99 (closer to 1.00 is desired). Specific model information is shown in the figure 3.

243

244

245

246

247


**Overview**

<b>Name</b>	Weibull Model
<b>Kind</b>	Regression
<b>Family</b>	Sigmoidal Models
<b>Equation</b>	$y = a - b \cdot \exp(-c \cdot x^d)$
<b># of Indep. Vars</b>	1
<b>Weighting</b>	Default
<b>Standard Error</b>	0.022830668235798594
<b>Correlation Coeff. (r)</b>	0.994782
<b>Coeff. of Determination (r^2)</b>	0.9895911573703048
<b>DOF</b>	17
<b>AICC</b>	-155.771049

**Parameters**

	Value	Std Err	Range (95% confidence)
<b>a</b>	1.440984	0.013098	1.413350 to 1.468618
<b>b</b>	0.486479	0.015155	0.454504 to 0.518453
<b>c</b>	0.000000	0.000000	-0.000000 to 0.000000
<b>d</b>	11.748741	1.621902	8.326827 to 15.170655

248



249

Figure 3. Weibull statistical analysis of Hook effect data

250

251

3.3 Clinical Evaluation:

252

A total of n=183 samples were collected during the clinical evaluation. A total of n=183 test samples utilizing the subject device resulted in the same result (i.e., positive or negative) in comparison to the control, except two (n=2) test sample rendered a positive result when using the subject device and a negative result when using the control. One (n=1) test samples rendered a negative result when using the subject device and a positive result when using the control. After conducting statistical analysis, a 98.4% degree of accuracy is established based on the data set (Table 6).

253

254

255

256

257

258

259

260

**Accuracy in Overall Patient Population**

261

The test results include 79 True Positives (RT-PCR Positives) and 104 True negatives (RT-PCR Negatives) (data in Table 2 in supplemental materials). When we analyzed the performance of the Kaya17 assay in overall population, the PPA value is calculated to be 98.7% and at 95% Confidence Interval, values are found to be at (93.2% Lower bound, 99.8% Upper bound).

262

263

264

265

266

267

268

269

**Table 6: Accuracy in Overall Patient Population**

		PCR Reference Result			Agreement		
Comparator Assay	Test Result	Positive	Negative	Total	Measure [a]	% (n/N)	95% CI [b]
Kaya17 (Overall)	Positive	78	2	80	PPA	98.7 (78/79)	(93.2, 99.8)
	Negative	1	102	103	NPA	98.1 (102/104)	(93.3, 99.5)
	Total	79	104	183	OPA	98.4 (180/183)	(95.3, 99.4)

[a] PPA=Positive Percent Agreement, NPA=Negative Percent Agreement, OPA=Overall Percent Agreement.  
 [b] Wilson Score Confidence Interval.

**Accuracy in Symptomatic Patient Population**

In the Symptomatic population (Table 7), there are 73 RT-PCR positives (True Positives) and 45 RT-PCR negatives (True Negatives). When we analyzed the performance of the Kaya17 assay in symptomatic population, the PPA value is calculated to be 98.6% and at 95% *Confidence Interval*, values are found to be at (92.60% Lower bound, 99.8% Upper bound).

**Table 7: Accuracy in Symptomatic Patient Population**

		PCR Reference Result			Agreement		
Comparator Assay	Test Result	Positive	Negative	Total	Measure [a]	% (n/N)	95% CI [b]
Kaya17 (Symptomatic)	Positive	72	1	73	PPA	98.6 (72/73)	(92.6, 99.8)
	Negative	1	44	45	NPA	97.8 (44/45)	(88.4, 99.6)
	Total	73	45	118	OPA	98.3 (116/118)	(94.0, 99.5)

[a] PPA=Positive Percent Agreement, NPA=Negative Percent Agreement, OPA=Overall Percent Agreement.  
 [b] Wilson Score Confidence Interval.

As seen in the raw data in Table 2 in the supplementary section, the nCovega test was able to detect the SARS-COV-2 virus as early as day 1 from the onset of symptoms.

### Accuracy in Asymptomatic Patient Population

In the Asymptomatic population (Table 8), there are 6 RT-PCR positives (True Positives) and 59 RT-PCR negatives (True Negatives). When we analyzed the performance of the Kaya17 assay in asymptomatic population, the PPA value is calculated to be 100% and at 95% Confidence Interval, values are found to be at (61% Lower bound, 100% Upper bound).

**Table 8: Accuracy in Asymptomatic Patient Population**

Comparator Assay	Test Result	PCR Reference Result			Agreement		
		Positive	Negative	Total	Measure [a]	% (n/N)	95% CI [b]
Kaya17 (Asymptomatic)	Positive	6	1	7	PPA	100.0 (6/6)	(61.0, 100.0)
	Negative	0	58	58	NPA	98.3 (58/59)	(91.0, 99.7)
	Total	6	59	65	OPA	98.5 (64/65)	(91.8, 99.7)


[a] PPA=Positive Percent Agreement, NPA=Negative Percent Agreement, OPA=Overall Percent Agreement.  
[b] Wilson Score Confidence Interval.

The operator specific accuracy is measured to support the POC Study to demonstrate that the Kaya17 nCoVega COVID-19 Antigen test can be performed by the untrained operator following the Quick Reference Guide without any training. Each untrained operator has achieved the 95% accuracy. Please refer to the Table 9.

**Table 9: Test results for each untrained operator.**

S.No	Operator	Total No. Samples Tested	Correctly measured w.r.t Control	Accuracy (%)
1	Operator 1	41	39	95.1
2	Operator 2	36	36	100
3	Operator 3	39	39	100
4	Operator 4	43	42	97.7
5	Operator 5	54	54	100

It is also observed that there is no reader instrument variability while interpreting the results when the samples are tested. All the RT-PCR comparative results correlate with the Kaya17 results when 5 different reader instruments were used for testing by 5 different untrained operators.



**Figure 4:** Inverse Relationship between Kaya17 RFUs vs Ct values from RT-PCR

Figure 4 shows the inverse linear relationship between the observed Kaya17 RFUs versus the mean values of the N and ORF1ab Gene cycle thresholds (n=183, Pearson Correlation= -0.92). The figure shows that all of the negative samples by PCR were also Negative in Kaya17 nCoVega test, except for two samples (Sample Number 31 and 117), all positive samples by PCR were also positive by Kaya17 nCoVega test, except for one sample (Sample Number 10).

### Discussion:

The Kaya17 Vega-200 system and nCoVega antigen test is a simple-to-use, rapid assay that is also highly sensitive and specific. The test can detect very low levels of SARS-CoV-2 as seen in the high correlation with RT-PCR across all ranges of viral loads, all the way down to Ct counts of 38. The test also confirmed its capability to detect infected people as early as Day 1 from the start of symptoms. The reader instrument is light, portable and runs off USB-power from its connected laptop, so it does not need external power source. The system can also process 30-50 samples in one hour and can be run by untrained operators, making it a very useful test to apply at point of care sites for accurate detection of infected people very early before they spread the virus to others. The low LOD of 20 TCID<sub>50</sub>/ml validates a sensitivity that is similar to RT-PCR (7) and several orders of magnitude more accurate/sensitive than most other antigen tests (13). A test like this with PCR-like sensitivity



and accuracy has significant implications in surveillance and population control, especially given its use of small volume of saliva sample which is very easy and non-invasive for all ages of subjects. The software, instrument and disposables including cartridge, provide an end-to-end solution that can be deployed in mobile units, at schools, offices and events and also in remote areas, given the instrument's small footprint and portability. Easily scalable manufacturing processes allow this test to meet any surge in demand for COVID-19 testing, as we open our schools, businesses and global travel and as new variants emerge. In the future, this test system can be productized for self-testing purposes. The nCoVega test can address the unmet need for rapid, accurate and inexpensive COVID-19 testing and it is suitable for broader public dissemination.

## References

1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.* 2019, 17(3), 181-192.
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 2020, 579(7798), 270-273.
3. Contini C, Di Nuzzo M, Barp N, et al. The novel zoonotic COVID-19 pandemic: An expected global health concern. *J Infect Dev Ctries.* 2020, 14(3), 254-264.
4. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nat Med.* 2020, 26(4):506-510.
5. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period [published online ahead of print, 2020 Apr 14]. *Science.* 2020; eabb5793.
6. Dwarakanath, S et al, Ultrasensitive Fluorescent Nanoparticle-Based Binding Assays for Foodborne and Waterborne Pathogens of Clinical Interest, *J. of Clinical Ligand Assay*, Fall 2006, Vol 29, No 3.
7. Altamimi, AM, Obeid, DA, Alaifan, TA, Taha, MT, Alhothali, MT, Alzahrani, FA, & Albarrag, AM. Assessment of 12 Qualitative RT-PCR commercial kits for the detection of SARS-CoV-2. *Journal of medical virology*, 2021, 10.1002/jmv.26900
8. Eshghifar, N., Busheri, A., Shrestha, R., & Beqaj, S. Evaluation of Analytical Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus. *International journal of general medicine*, 2021, 14, 435-440.
9. Mak GC, Lau SS, Wong KK, Chow NL, Lau CS, Lam ET, Chan RC, Tsang DN. Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. *J Clin Virol.* 2020 Dec;133:104684
10. Kohmer N, Toptan T, Pallas C, et al. The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *J Clin Med.* 2021, 10(2), 328.
11. Currie L (1968). Limits for qualitative detection and quantitative determination. Application to radiochemistry. *Anal. Chem.* 1968, 40, 3, 586-593.
12. CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
13. Weissleder R, Hakho L, Ko J, and Pittet M. COVID-19 diagnostics in context. *Science Translational Medicine.* 3 Jun 2020. Vol 12, Issue 54, p6.

**Author Contributions:** SD and VM conceived the study and cross-platform validation experiments at ASU. SS led the design and development of the Vega-200 system. SD, CBT, TC, AM, DM developed and optimized the nCoVega SARS-CoV-2 assay. DM and SD ran the analytical study. SD, CBT ran the clinical validation study at ASU. JC, JM and CBT analyzed the data. TC, SM and SD drafted the manuscript. CBT revised the manuscript. All authors read and approved the final manuscript.

**Funding:** This research received no external funding

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, 374  
and approved by the Institutional Review Board (or Ethics Committee) of Western IRB (IRB protocol #20204097; Kaya17 375  
protocol #KAYA-PROTOPOCT-007 Rev002) on 01/06/2021. 376

377

378

Supplementary Materials

379  
380  
381  
382  
383  
384  
385

Table 1: LOD LOB testing raw data

Operator: Arsh  
ReaderID: R6

ID	Bgd_Rdg	Thr_Rdg	Raw_Avg	Test_Results	Sample_Name
C1	-2.362	0.3	0.298	NEG	NEG Control
C2	-2.362	0.3	0.347	POS	POS control
S3	-2.362	0.3	0.337	POS	20
S4	-2.362	0.3	0.333	POS	20
S5	-2.362	0.3	0.336	POS	20
S6	-2.362	0.3	0.338	POS	20
S7	-2.362	0.3	0.331	POS	20
S8	-2.362	0.3	0.334	POS	20
S9	-2.362	0.3	0.333	POS	20
S10	-2.362	0.3	0.335	POS	20
S11	-2.362	0.3	0.334	POS	20
S12	-2.362	0.3	0.337	POS	20
S13	-2.362	0.3	0.338	POS	20
S14	-2.362	0.3	0.333	POS	20
S15	-2.362	0.3	0.338	POS	20
S16	-2.362	0.3	0.336	POS	20
S17	-2.362	0.3	0.335	POS	20
S18	-2.362	0.3	0.336	POS	20
S19	-2.362	0.3	0.331	POS	20
S20	-2.362	0.3	0.332	POS	20
S21	-2.362	0.3	0.331	POS	20
S22	-2.362	0.3	0.335	POS	20
S23	-2.362	0.3	0.3	NEG	0
S24	-2.362	0.3	0.3	NEG	0
S25	-2.362	0.3	0.299	NEG	0
S26	-2.362	0.3	0.3	NEG	0
S27	-2.362	0.3	0.3	NEG	0
S28	-2.362	0.3	0.299	NEG	0
S29	-2.362	0.3	0.3	NEG	0
S30	-2.362	0.3	0.298	NEG	0
S31	-2.362	0.3	0.3	NEG	0
S32	-2.362	0.3	0.3	NEG	0
S33	-2.362	0.3	0.3	NEG	0
S34	-2.362	0.3	0.298	NEG	0

S35	-2.362	0.3	0.3	NEG	0
S36	-2.362	0.3	0.3	NEG	0
S37	-2.362	0.3	0.3	NEG	0
S38	-2.362	0.3	0.3	NEG	0
S39	-2.362	0.3	0.3	NEG	0
S40	-2.362	0.3	0.297	NEG	0
S41	-2.362	0.3	0.3	NEG	0
S42	-2.362	0.3	0.299	NEG	0

386  
387  
388  
389

TABLE 1a: Results of 20 replicates for LoD and LoB confirmation

ID	Raw Average	TCID <sub>50</sub> /mL
S3	0.337	20
S4	0.333	20
S5	0.336	20
S6	0.338	20
S7	0.331	20
S8	0.334	20
S9	0.333	20
S10	0.335	20
S11	0.334	20
S12	0.337	20
S13	0.338	20
S14	0.333	20
S15	0.338	20
S16	0.336	20
S17	0.335	20
S18	0.336	20
S19	0.331	20
S20	0.332	20
S21	0.331	20
S22	0.335	20
S23	0.3	0
S24	0.3	0
S25	0.299	0
S26	0.3	0
S27	0.3	0
S28	0.299	0
S29	0.3	0
S30	0.298	0
S31	0.3	0
S32	0.3	0
S33	0.3	0
S34	0.298	0
S35	0.3	0
S36	0.3	0
S37	0.3	0
S38	0.3	0
S39	0.3	0
S40	0.297	0
S41	0.3	0
S42	0.299	0

**SD of 20 TCID<sub>50</sub>/mL Samples**  
0.00237

**Mean of LoD Samples:**  
0.335

**Mean of Blank Samples:**  
0.300

**SD of Blank Samples:**  
0.00089

SD = Standard Deviation

390  
391  
392

Table 2: Clinical Test Results for PE Nucleic Acid Detection Kit and Kaya17 nCoVega Test

393  
394  
395  
396  
397  
398

Sample	Date of onset of symptoms	#of days Post symptom	N Gene	IC	ORF1ab	PE RESULT	Kaya17 (RFU)	Kaya17 RESULT	Operator
NP-1	-	No Symptom	UND	36.77	UND	NOT DETECTED	0.275	NEG	1
NP-2	24-May-21	1 day	30.05	33.47	30.07	DETECTED	0.392	POS	
NP-3	-	No Symptom	UND	33.84	UND	NOT DETECTED	0.266	NEG	
NP-4	-	No Symptom	UND	32.56	UND	NOT DETECTED	0.268	NEG	
NP-5	-	No Symptom	UND	33.47	UND	NOT DETECTED	0.289	NEG	
NP-6	-	No Symptom	UND	34.90	UND	NOT DETECTED	0.292	NEG	
NP-7	-	No Symptom	UND	33.59	UND	NOT DETECTED	0.284	NEG	
NP-8	23-May-21	2 Days	22.87	33.53	22.67	DETECTED	0.64	POS	
NP-9	-	No Symptom	UND	33.64	UND	NOT DETECTED	0.281	NEG	
NP-10	23-May-21	2 Days	30.59	35.99	31.96	DETECTED	0.293	NEG	
NP-11	23-May-21	2 Days	31.49	33.79	UND	DETECTED	0.385	POS	
NP-12	22-May-21	3 Days	33.10	33.56	35.57	DETECTED	0.382	POS	
NP-13	-	No Symptom	24.81	33.01	25.53	DETECTED	0.562	POS	

NP-14	24-May-21	1 day	29.64	34.02	29.71	DETECTED	0.396	POS
NP-15	23-May-21	2 Days	19.83	32.21	20.71	DETECTED	0.767	POS
NP-16	-	No Symptom	UND	31.14	UND	NOT DETECTED	0.279	NEG
NP-17	-	No Symptom	UND	33.67	UND	NOT DETECTED	0.284	NEG
NP-18	-	No Symptom	UND	33.15	UND	NOT DETECTED	0.278	NEG
NP-19	23-May-21	2 Days	27.92	32.49	23.68	DETECTED	0.446	POS
NP-20	24-May-21	1 day	UND	33.75	UND	NOT DETECTED	0.288	NEG
NP-21	22-May-21	3 Days	32.94	33.16	34.98	DETECTED	0.383	POS
NP-22	-	No Symptom	UND	32.56	UND	NOT DETECTED	0.295	NEG
NP-23	22-May-21	3 Days	17.86	33.58	17.55	DETECTED	0.845	POS
NP-24	-	No Symptom	UND	33.63	UND	NOT DETECTED	0.287	NEG
NP-25	-	No Symptom	UND	32.89	UND	NOT DETECTED	0.293	NEG
NP-26	-	No Symptom	UND	34.45	UND	NOT DETECTED	0.276	NEG
NP-27	22-May-21	3 Days	27.42	33.36	26.99	DETECTED	0.448	POS
NP-28		No Symptom	UND	33.31	UND	NOT DETECTED	0.296	NEG
NP-29	24-May-21	1 day	32.99	32.23	34.33	DETECTED	0.388	POS

NP-30	22-May-21	3 Days	19.55	33.49	19.75	DETECTED	0.763	POS	2
NP-31	-	No Symptom	UND	31.48	UND	NOT DETECTED	0.323	POS	
NP-32	-	No Symptom	UND	32.89	UND	NOT DETECTED	0.293	NEG	
NP-33	-	No Symptom	UND	33.02	UND	NOT DETECTED	0.278	NEG	
NP-34	22-May-21	3 Days	28.52	33.94	28.70	DETECTED	0.38	POS	
NP-35	22-May-21	3 Days	33.95	33.58	34.86	DETECTED	0.376	POS	
NP-36	-	No Symptom	UND	34.46	UND	NOT DETECTED	0.278	NEG	
NP-37	-	No Symptom	UND	33.92	UND	NOT DETECTED	0.294	NEG	
NP-38	-	No Symptom	UND	32.53	UND	NOT DETECTED	0.288	NEG	
NP-39	25-May-21	3 Days	28.82	35.67	28.30	DETECTED	0.401	POS	
NP-40	27-May-21	1 day	UND	36.41	UND	NOT DETECTED	0.287	NEG	
NP-41	-	No Symptom	UND	33.23	UND	NOT DETECTED	0.298	NEG	
NP-42	-	No Symptom	UND	32.34	UND	NOT DETECTED	0.272	NEG	
NP-43	-	No Symptom	UND	33.63	UND	NOT DETECTED	0.284	NEG	
NP-44	-	No Symptom	UND	32.22	UND	NOT DETECTED	0.281	NEG	



NP-45	-	No Symptom	UND	34.12	UND	NOT DETECTED	0.293	NEG
NP-46	-	No Symptom	UND	33.41	UND	NOT DETECTED	0.285	NEG
NP-47	-	No Symptom	UND	33.30	UND	NOT DETECTED	0.296	NEG
NP-48	-	No Symptom	UND	33.20	UND	NOT DETECTED	0.294	NEG
NP-49	-	No Symptom	UND	33.46	UND	NOT DETECTED	0.294	NEG
NP-50	-	No Symptom	UND	34.85	UND	NOT DETECTED	0.281	NEG
NP-51	-	No Symptom	UND	33.56	UND	NOT DETECTED	0.283	NEG
NP-52	-	No Symptom	UND	32.66	UND	NOT DETECTED	0.289	NEG
NP-53	-	No Symptom	UND	33.96	UND	NOT DETECTED	0.288	NEG
NP-54	27-May-21	1 day	34.32	32.80	34.16	DETECTED	0.375	POS
NP-55	-	No Symptom	UND	33.93	UND	NOT DETECTED	0.279	NEG
NP-56	26-May-21	2 Days	35.10	32.53	35.91	DETECTED	0.379	POS
NP-57	25-May-21	3 Days	18.76	33.67	19.82	DETECTED	0.817	POS
NP-58	27-May-21	1 day	34.40	32.93	33.86	DETECTED	0.387	POS

NP-59	-	No Symptom	UND	32.79	UND	NOT DETECTED	0.286	NEG	3
NP-60	-	No Symptom	UND	34.54	UND	NOT DETECTED	0.294	NEG	
NP-61	-	No Symptom	UND	33.64	UND	NOT DETECTED	0.287	NEG	
NP-62	-	No Symptom	UND	35.73	UND	NOT DETECTED	0.295	NEG	
NP-63	-	No Symptom	UND	33.16	UND	NOT DETECTED	0.291	NEG	
NP-64	-	No Symptom	UND	35.99	UND	NOT DETECTED	0.296	NEG	
NP-65	-	No Symptom	UND	32.35	UND	NOT DETECTED	0.279	NEG	
NP-66	-	No Symptom	UND	33.90	UND	NOT DETECTED	0.289	NEG	
NP-67	-	No Symptom	UND	34.65	UND	NOT DETECTED	0.293	NEG	
NP-68	3-Jun-21	2 Days	23.55	33.55	24.67	DETECTED	0.675	POS	
NP-69	4-Jun-21	1 day	34.74	32.82	35.92	DETECTED	0.377	POS	
NP-70	2-Jun-21	3 Days	25.66	33.78	UND	DETECTED	0.555	POS	
NP-71	3-Jun-21	2 Days	26.11	33.00	28.00	DETECTED	0.479	POS	
NP-72	--	No Symptom	UND	34.75	UND	NOT DETECTED	0.288	NEG	
NP-73	-	No Symptom	UND	35.03	UND	NOT DETECTED	0.284	NEG	
NP-74	-	No Symptom	35.16	33.87	36.84	DETECTED	0.368	POS	

NP-75	4-Jun-21	1 day	35.30	33.85	33.48	DETECTED	0.379	POS
NP-76	-	No Symptom	UND	35.00	UND	NOT DETECTED	0.288	NEG
NP-77	-	No Symptom	UND	34.78	UND	NOT DETECTED	0.292	NEG
NP-78	-	No Symptom	UND	33.98	UND	NOT DETECTED	0.296	NEG
NP-79	-	No Symptom	UND	35.67	UND	NOT DETECTED	0.289	NEG
NP-80	-	No Symptom	UND	34.79	UND	NOT DETECTED	0.293	NEG
NP-81	-	No Symptom	39.23	33.18	UND	DETECTED	0.329	POS
NP-82	3-Jun-21	2 Days	35.63	33.12	34.82	DETECTED	0.366	POS
NP-83	-	No Symptom	UND	34.63	UND	NOT DETECTED	0.287	NEG
NP-84	-	No Symptom	UND	34.56	UND	NOT DETECTED	0.276	NEG
NP-85	-	No Symptom	UND	33.78	UND	NOT DETECTED	0.293	NEG
NP-86	3-Jun-21	2 Days	18.87	34.01	19.05	DETECTED	0.842	POS
NP-87	3-Jun-21	2 Days	25.12	33.43	24.93	DETECTED	0.528	POS
NP-88	3-Jun-21	2 Days	26.76	33.72	26.40	DETECTED	0.492	POS
NP-89	-	No Symptom	UND	32.91	UND	NOT DETECTED	0.294	NEG
NP-90	-	No Symptom	UND	33.54	UND	NOT DETECTED	0.296	NEG
NP-91	4-Jun-21	1 day	33.74	31.96	34.55	DETECTED	0.39	POS
NP-92	3-Jun-21	2 Days	28.52	33.60	29.88	DETECTED	0.421	POS

NP-93	4-Jun-21	1 day	35.47	33.66	35.45	DETECTED	0.376	POS	4
NP-94	3-Jun-21	2 Days	22.45	33.41	21.77	DETECTED	0.674	POS	
NP-95	-	No Symptom	UND	33.03	UND	NOT DETECTED	0.286	NEG	
NP-96	-	No Symptom	UND	32.91	UND	NOT DETECTED	0.288	NEG	
NP-97	-	No Symptom	UND	35.30	UND	NOT DETECTED	0.294	NEG	
NP-98	-	No Symptom	UND	33.84	UND	NOT DETECTED	0.295	NEG	
NP-99	-	No Symptom	UND	34.77	UND	NOT DETECTED	0.293	NEG	
NP-100	5-Jun-21	1 day	34.33	32.07	34.50	DETECTED	0.374	POS	
NP-101	5-Jun-21	1 day	UND	32.10	UND	NOT DETECTED	0.295	NEG	
NP-102	-	No Symptom	UND	32.21	UND	NOT DETECTED	0.296	NEG	
NP-103	-	No Symptom	UND	32.42	UND	NOT DETECTED	0.287	NEG	
NP-104	5-Jun-21	1 day	34.46	32.29	34.85	DETECTED	0.371	POS	
NP-105	-	No Symptom	37.67	32.55	38.11	DETECTED	0.368	POS	
NP-106	-	No Symptom	UND	31.77	UND	NOT DETECTED	0.288	NEG	
NP-107	-	No Symptom	UND	34.54	UND	NOT DETECTED	0.279	NEG	
NP-108	-	No Symptom	UND	33.32	UND	NOT DETECTED	0.293	NEG	

NP-109	-	No Symptom	UND	33.65	UND	NOT DETECTED	0.294	NEG
NP-110	5-Jun-21	1 day	35.98	32.73	36.01	DETECTED	0.366	POS
NP-111	4-Jun-21	2 Days	34.66	33.21	34.97	DETECTED	0.37	POS
NP-112	4-Jun-21	2 Days	26.43	34.88	27.98	DETECTED	0.487	POS
NP-113	4-Jun-21	2 Days	30.12	31.44	UND	DETECTED	0.396	POS
NP-114	-	No Symptom	UND	32.28	UND	NOT DETECTED	0.285	NEG
NP-115	-	No Symptom	UND	32.69	UND	NOT DETECTED	0.296	NEG
NP-116	-	No Symptom	UND	34.55	UND	NOT DETECTED	0.288	NEG
NP-117	-	1 day	UND	33.99	UND	NOT DETECTED	0.329	POS
NP-118	-	No Symptom	UND	33.24	UND	NOT DETECTED	0.295	NEG
NP-119	-	No Symptom	UND	33.40	UND	NOT DETECTED	0.293	NEG
NP-120	-	No Symptom	UND	32.59	UND	NOT DETECTED	0.289	NEG
NP-121	5-Jun-21	1 day	31.54	32.73	30.98	DETECTED	0.387	POS
NP-122	4-Jun-21	2 Days	33.39	33.11	33.28	DETECTED	0.379	POS
NP-123	-	No Symptom	UND	36.46	UND	NOT DETECTED	0.297	NEG
NP-124	2-Jun-21	4 days	22.85	33.26	22.37	DETECTED	0.646	POS
NP-125	-	No Symptom	UND	33.55	UND	NOT DETECTED	0.288	NEG
NP-126	-	No Symptom	UND	31.67	UND	NOT DETECTED	0.285	NEG

NP-127	-	No Symptom	UND	34.21	UND	NOT DETECTED	0.295	NEG
NP-128	-	No Symptom	UND	33.44	UND	NOT DETECTED	0.296	NEG
NP-129	-	No Symptom	UND	32.45	UND	NOT DETECTED	0.292	NEG
NP-130	3-Jun-21	3 Days	14.73	32.65	15.10	DETECTED	1.272	POS
NP-131	5-Jun-21	1 day	21.58	33.32	21.99	DETECTED	0.683	POS
NP-132	5-Jun-21	1 day	33.97	33.48	35.56	DETECTED	0.384	POS
NP-133	4-Jun-21	2 Days	35.25	33.77	36.95	DETECTED	0.368	POS
NP-134	4-Jun-21	2 Days	32.89	34.25	34.22	DETECTED	0.381	POS
NP-135	5-Jun-21	1 day	35.33	33.92	35.02	DETECTED	0.374	POS
NP-136	-	No Symptom	37.74	34.67	38.08	DETECTED	0.361	POS
NP-137	23-Jun-21	4 days	15.76	32.69	15.59	DETECTED	0.921	POS
NP-138	-	No Symptom	UND	32.29	UND	NOT DETECTED	0.285	NEG
NP-139	-	No Symptom	UND	31.90	UND	NOT DETECTED	0.296	NEG
NP-140	-	No Symptom	UND	32.65	UND	NOT DETECTED	0.293	NEG
NP-141	-	No Symptom	UND	32.98	UND	NOT DETECTED	0.297	NEG
NP-142	25-Jun-21	2 Days	35.17	32.28	34.66	DETECTED	0.327	POS
NP-143	-	No Symptom	UND	33.58	UND	NOT DETECTED	0.295	NEG
NP-144	25-Jun-21	2 Days	33.75	33.88	33.21	DETECTED	0.384	POS

NP-145	24-Jun-21	3 Days	33.76	32.55	34.86	DETECTED	0.388	pos
NP-146	24-Jun-21	3 Days	29.58	33.75	29.57	DETECTED	0.397	POS
NP-147	24-Jun-21	3 Days	21.65	33.45	21.50	DETECTED	0.683	POS
NP-148	-	No Symptom	39.00	32.71	37.06	DETECTED	0.328	POS
NP-149	-	No Symptom	UND	31.90	UND	NOT DETECTED	0.296	NEG
NP-150	25-Jun-21	2 Days	34.79	32.56	36.85	DETECTED	0.374	POS
NP-151	25-Jun-21	2 Days	35.02	32.32	34.62	DETECTED	0.377	POS
NP-152	-	No Symptom	UND	34.56	UND	NOT DETECTED	0.293	NEG
NP-153	-	No Symptom	UND	33.67	UND	NOT DETECTED	0.293	NEG
NP-154	-	No Symptom	UND	33.84	UND	NOT DETECTED	0.287	NEG
NP-155	25-Jun-21	2 Days	35.22	32.18	36.37	DETECTED	0.374	POS
NP-156	26-Jun-21	1 day	34.82	33.00	34.67	DETECTED	0.375	POS
NP-157	26-Jun-21	1 day	34.48	32.91	34.44	DETECTED	0.372	POS
NP-158	-	No Symptom	UND	33.10	UND	NOT DETECTED	0.296	NEG
NP-159	-	No Symptom	UND	33.87	UND	NOT DETECTED	0.293	NEG
NP-160	-	No Symptom	UND	33.04	UND	NOT DETECTED	0.295	NEG

NP-161	-	No Symptom	UND	32.29	UND	NOT DETECTED	0.294	NEG
NP-162	26-Jun-21	1 day	UND	33.46	UND	NOT DETECTED	0.295	NEG
NP-163	-	No Symptom	UND	33.85	UND	NOT DETECTED	0.297	NEG
NP-164	-	No Symptom	UND	34.06	UND	NOT DETECTED	0.294	NEG
NP-165	-	No Symptom	UND	31.54	UND	NOT DETECTED	0.295	NEG
NP-166	26-Jun-21	1 day	36.03	33.01	34.70	DETECTED	0.365	POS
NP-167	26-Jun-21	1 day	UND	30.97	38.06	DETECTED	0.328	POS
NP-168	25-Jun-21	2 Days	UND	33.15	38.87	DETECTED	0.325	POS
NP-169	25-Jun-21	2 Days	35.31	32.80	35.16	DETECTED	0.376	POS
NP-170	26-Jun-21	1 day	37.82	33.47	38.92	DETECTED	0.365	POS
NP-171	25-Jun-21	2 Days	30.79	34.47	29.69	DETECTED	0.392	POS
NP-172	24-Jun-21	3 Days	31.62	33.25	32.08	DETECTED	0.383	POS
NP-173	-	No Symptom	UND	36.19	UND	NOT DETECTED	0.297	NEG
NP-174	24-Jun-21	3 Days	26.75	34.21	26.73	DETECTED	0.482	POS
NP-175	23-Jun-21	4 Days	27.52	33.68	27.59	DETECTED	0.447	POS
NP-176	22-Jun-21	5 Days	29.30	34.07	29.27	DETECTED	0.398	POS
NP-177	-	No Symptom	UND	33.13	UND	NOT DETECTED	0.293	NEG



NP-178	26-Jun-21	1 day	33.56	33.41	36.53	DETECTED	0.38	POS
NP-179	26-Jun-21	1 day	35.30	32.72	35.66	DETECTED	0.372	POS
NP-180	25-Jun-21	2 Days	34.86	33.66	36.34	DETECTED	0.369	POS
NP-181	25-Jun-21	2 Days	35.80	33.63	37.02	DETECTED	0.364	POS
NP-182	-	No Symptom	UND	34.56	UND	NOT DETECTED	0.292	NEG
NP-183	-	No Symptom	UND	33.55	UND	NOT DETECTED	0.297	NEG

UND=Undetected, NEG=Negative, POS=Positive

399

400

401